Söderlin M K, Lindroth Y, Jacobsson L T H
Consultant Rheumatologist, Spenshult Rheumatology Hospital, 313 92, Oskarström, Sweden.
Rheumatology (Oxford). 2007 Aug;46(8):1355-8. doi: 10.1093/rheumatology/kem143. Epub 2007 Jun 13.
To study trends in treatment, health status and health-related quality of life (HRQL) in two cross-sectional surveys over a 5-yr period and in an observational follow-up sub-cohort based on a population-based rheumatoid arthritis (RA) register in Malmö, Sweden.
A continuously updated population-based RA register was established in Malmö city in southern Sweden in 1997. Patient-administered questionnaires in 1997 and 2002 were used to collect information on demographics, medication and health status. Cross-sectional comparisons were made between 1997 and 2002. A longitudinal analysis was also performed in the RA patients participating in both surveys.
Increased proportions of patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) (69 vs 52%), corticosteroids (30 vs 23%), methotrexate (52 vs 29%) and biologics (14 vs 0%) in 2002 compared with 1997. In the cross-sectional analysis, the visual analogue scores (VAS) for pain and general health and the short form 36 (SF-36) domains were slightly better in 2002 than in 1997. In the observational sub-cohort, patients treated with biologics improved significantly in several measures of health status, whereas those starting on methotrexate or undergoing other or no changes in DMARD therapy did not.
In this population-based RA cohort, patients were more actively treated in 2002. Small improvements were seen in health status and these improvements were exclusively attributable to treatment with biologics.
通过两项为期5年的横断面调查以及一项基于瑞典马尔默人群类风湿性关节炎(RA)登记册的观察性随访亚队列研究,探究治疗、健康状况及健康相关生活质量(HRQL)的变化趋势。
1997年在瑞典南部的马尔默市建立了一个持续更新的基于人群的RA登记册。1997年和2002年采用患者自填问卷收集人口统计学、用药及健康状况信息。对1997年和2002年的数据进行横断面比较。同时对参与两项调查的RA患者进行纵向分析。
与1997年相比,2002年接受改善病情抗风湿药物(DMARDs)治疗的患者比例增加(69%对52%),接受皮质类固醇治疗的患者比例增加(30%对23%),接受甲氨蝶呤治疗的患者比例增加(52%对29%),接受生物制剂治疗的患者比例增加(14%对0%)。在横断面分析中,2002年疼痛和总体健康状况的视觉模拟评分(VAS)以及简短健康调查问卷(SF-36)各领域得分略高于1997年。在观察性亚队列中,接受生物制剂治疗的患者在多项健康状况指标上有显著改善,而开始使用甲氨蝶呤或DMARD治疗无变化或接受其他治疗的患者则没有改善。
在这个基于人群的RA队列中,2002年患者接受了更积极的治疗。健康状况有小幅改善,且这些改善完全归因于生物制剂治疗。